SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Board appointment

12 Nov 2015 07:00

RNS Number : 4321F
Silence Therapeutics PLC
12 November 2015
 



 

 

 

Board appointment

12th November 2015

 

Silence Therapeutics plc

 

 

Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, is pleased to announced the appointment of Alistair Gray as Non-Executive Director of the Company, with immediate effect. Alistair will also Chair the Audit Committee.

 

Alistair brings with him a wealth of consultancy and business experience. Having trained as an accountant, his early career was in senior management positions with Unilever and John Wood Group PLC. Alistair was a Director of Arthur Young (now Ernst and Young) Management Consultants and PA Consulting Group. Alistair founded Genesis Consulting and, most recently, Renaissance & Company, a strategic management consultancy working with clients across business and sport.

 

Alistair has served as Executive Chairman of the Winning Scotland Foundation and previously served as Chair of British Swimming and British Basketball, leading significant change in both sports. Alistair is currently Chairman of Edrington's Pension Trustees, responsible for management of a major private pension fund and also Chair of the trading division of John Hogg & Company. Alistair chaired the Audit and Remuneration committees of AorTech International PLC and Highland Distillers PLC, as well as the Pension Trustee Board. Alistair also served as a Fellow of the Institute of Directors and Institute of Consultants.

 

 

Stephen Parker Ph.D.  Non-Executive Chairman of Silence Therapeutics, said:

"We are delighted to welcome Alistair to the Board of Silence Therapeutics. His expertise in strategic leadership will be invaluable as we continue to expand our business and seek to deliver value to our shareholders."

 

 

Alistair William Gray, age 67, holds no shares in the Company. He holds or has held the following directorships within the last five years:

 

Current

Renaissance & Company Limited

 

Past

Winning Scotland Foundation (formerly The Scottish Institute of Sport Foundation)

British Swimming Limited

High Performance Swimming Limited

pmpgenesis Limited

Genesis Consulting Limited - dissolved

Genesis Research Limited - dissolved

Genesis Subsidiary Limited - dissolved

Genesis Red Limited - dissolved

 

Genesis Consulting Ltd, a company founded in 1992 by Alistair Gray was put into compulsory liquidation in February 2010. The associated companies were also dissolved.

 

Save as set out above, there are no further disclosures pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

 

 

 

Enquiries:

 

Silence Therapeutics plc

Ali Mortazavi, Chief Executive Officer

Timothy Freeborn, Chief Financial Officer

Tel: +44 (0)20 3457 6900

 

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)

Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel

Tel: +44 (0)20 7523 8350

 

 

Peel Hunt LLP (Joint Broker)

James Steel/Dr Tom Burt/Oliver Jackson

 

Tel: +44 (0)20 7418 8900

Media Enquiries:

FTI Consulting

Simon Conway/Brett Pollard/Stephanie Cuthbert

Tel: +44 (0) 20 3727 1000

 

 

 

 

Notes to Editors

 

About Silence Therapeutics plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet medical need. In 2015 Silence announced interim results from a Phase 2a pancreatic cancer trial using its compound, Atu027, in combination with gemcitabine.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMMMMMMKGKZZ
Date   Source Headline
30th Jul 200812:00 pmPRNStatement re Update Regarding Milestone Payment
25th Jul 200810:57 amPRNHolding(s) in Company
24th Jul 20082:00 pmPRNTiming of AGM and Interim Results
24th Jul 20087:00 amPRNHolding(s) in Company
11th Jul 200812:12 pmPRNStatement re Successful Patent Opposition
1st Jul 20087:00 amPRNDirectorate Change
25th Jun 200812:30 pmPRNResearch Update
25th Jun 20087:00 amPRNAnnual Report and Accounts
24th Jun 20083:50 pmPRNHolding(s) in Company
18th Jun 20081:10 pmPRNHolding(s) in Company
9th Jun 20087:00 amRNSPresentations at upcoming con
5th Jun 20087:00 amPRNHolding(s) in Company
16th May 20082:05 pmPRNHolding(s) in Company
6th May 20089:00 amRNSPresentation at Conference
7th Apr 20084:12 pmRNSHolding(s) in Company
7th Apr 20087:01 amRNSDevelopment Concept Supported
1st Apr 20087:05 amPRNDirector/PDMR Shareholding
31st Mar 20087:49 amPRNDirector/PDMR Shareholding
27th Mar 20082:24 pmPRNHolding(s) in Company
27th Mar 20087:00 amPRNPreliminary Final Results
19th Mar 20082:30 pmPRNNotice of Results
19th Mar 200810:56 amPRNHolding(s) in Company
13th Mar 20082:15 pmPRNRe Agreement
13th Mar 200810:54 amPRNHolding(s) in Company
5th Feb 200811:00 amPRNHolding(s) in Company
31st Jan 20084:25 pmPRNHolding(s) in Company
30th Jan 20087:00 amPRNHolding(s) in Company
23rd Jan 200810:05 amPRNHolding(s) in Company
21st Jan 20084:09 pmPRNHolding(s) in Company
17th Jan 20087:00 amPRNHolding(s) in Company
7th Jan 20087:00 amPRNStatement re Chairman's Letter to Shareholders
2nd Jan 20084:25 pmPRNHolding(s) in Company
2nd Jan 200811:10 amPRNHolding(s) in Company
24th Dec 20077:00 amPRNDirector/PDMR Shareholding
17th Dec 20071:40 pmPRNStatement re Share Price Movement
14th Dec 20074:20 pmPRNHolding(s) in Company
12th Dec 20071:31 pmPRNHolding(s) in Company
4th Dec 20074:23 pmPRNHolding(s) in Company
26th Nov 20074:21 pmPRNHolding(s) in Company
23rd Nov 20073:30 pmPRNHolding(s) in Company
20th Nov 20077:00 amPRNChange of Nomad
19th Nov 20071:00 pmPRNResearch Update
19th Nov 20077:02 amRNSPresentation at Conference
5th Nov 20071:20 pmPRNHolding(s) in Company
2nd Nov 200712:35 pmPRNHolding(s) in Company
2nd Nov 20077:01 amRNSConference Attendance
30th Oct 200710:00 amPRNHolding(s) in Company
29th Oct 20074:15 pmPRNHolding(s) in Company
26th Oct 20074:15 pmPRNHolding(s) in Company
25th Oct 200711:10 amPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.